Multiple sclerosis (MS) in children and adolescents has received increased attention during the past decade. Although not tested in randomized placebo-controlled trials, first-line disease-modifying therapies are widely used in patients with MS who are younger than 18 years. This review summarizes current treatment practices, possible future treatment options, and gives insight into special problems in the treatment of pediatric patients with MS.
Georg Thieme Verlag KG Stuttgart · New York.